Literature DB >> 34081155

Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation.

Samuel Macy1, Jakob Passweg1, Michael Medinger2,3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34081155     DOI： 10.1007/s00277-021-04563-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

1.  Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

Authors:  Jan Styczynski; Gloria Tridello; Lidia Gil; Per Ljungman; Malgorzata Mikulska; Katherine N Ward; Catherine Cordonnier; Rafael de la Camara; Diana Averbuch; Nina Knelange; Gerard Socié; Patrice Chevallier; Didier Blaise; Ibrahim Yakoub-Agha; Edouard Forcade; Jan Cornelissen; Johan Maertens; Eefke Petersen; Stéphanie Nguyen-Quoc; Hendrik Veelken; Nicolaas Schaap; Jakob Passweg; Mauricette Michallet; Nathalie Fegueux; Eric Deconinck; Nigel Russell; Grzegorz Basak; Peter Bader; Silvia Montoto; Nicolaus Kröger; Simone Cesaro
Journal:  Bone Marrow Transplant       Date:  2019-07-30       Impact factor: 5.483

2.  Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.

Authors:  Sophie Auger; Mattea Orsini; Patrice Céballos; Nathalie Fegueux; Tarik Kanouni; Bastien Caumes; Bernard Klein; Martin Villalba; Jean-François Rossi
Journal:  Eur J Haematol       Date:  2014-02-15       Impact factor: 2.997

3.  Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  Hong Wang; Tong-Tong Zhang; Jia-Qian Qi; Tian-Tian Chu; Miao Miao; Hui-Ying Qiu; Cheng-Cheng Fu; Xiao-Wen Tang; Chang-Geng Ruan; De-Pei Wu; Yue Han
Journal:  Ann Hematol       Date:  2019-02-04       Impact factor: 3.673

4.  Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study.

Authors:  Diem-Lan Vu; Julie-Anne Dayer; Stavroula Masouridi-Levrat; Christophe Combescure; Elsa Boely; Nina Khanna; Nicolas J Mueller; Martina Kleber; Michael Medinger; Joerg Halter; Jakob Passweg; Antonia M Müller; Urs Schanz; Yves Chalandon; Dionysios Neofytos; Christian van Delden; Laurent Kaiser
Journal:  Transpl Infect Dis       Date:  2020-04-27       Impact factor: 2.228

5.  The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.

Authors:  Peng Ke; Xinyou Zhang; Songbai Liu; Qian Zhu; Xiao Ma; Feng Chen; Xiaowen Tang; Yue Han; ZhengZheng Fu; Suning Chen; Depei Wu; Huiying Qiu; Jihao Zhou; Xiebing Bao
Journal:  Ann Hematol       Date:  2021-04-22       Impact factor: 3.673

6.  Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.

Authors:  Michalina Kołodziejczak; Lidia Gil; Rafael de la Camara; Jan Styczyński
Journal:  Ann Hematol       Date:  2021-01-25       Impact factor: 3.673

7.  Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.

Authors:  Yuhua Ru; Xiang Zhang; Tiemei Song; Yiyang Ding; Ziling Zhu; Yi Fan; Yang Xu; Aining Sun; Huiying Qiu; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Suning Chen; Xiao Ma; Feng Chen; Jia Chen; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

8.  Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.

Authors:  Ling Zhou; Zhi-Yong Gao; Dao-Pei Lu
Journal:  Ann Hematol       Date:  2020-04-14       Impact factor: 3.673
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.